Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tsc1/Tsc2-dependent inhibition of TORC1.

Tran TA, Kinch L, Peña-Llopis S, Kockel L, Grishin N, Jiang H, Brugarolas J.

Mol Cell Biol. 2013 Oct;33(19):3762-79. doi: 10.1128/MCB.01570-12. Epub 2013 Jul 22.

3.

Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.

Gökmen-Polar Y, Liu Y, Toroni RA, Sanders KL, Mehta R, Badve S, Rommel C, Sledge GW Jr.

Breast Cancer Res Treat. 2012 Dec;136(3):673-82. doi: 10.1007/s10549-012-2298-8. Epub 2012 Oct 21.

PMID:
23085766
4.

Tuberous sclerosis complex regulates Drosophila neuromuscular junction growth via the TORC2/Akt pathway.

Natarajan R, Trivedi-Vyas D, Wairkar YP.

Hum Mol Genet. 2013 May 15;22(10):2010-23. doi: 10.1093/hmg/ddt053. Epub 2013 Feb 7.

5.

TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity.

Yang Q, Inoki K, Kim E, Guan KL.

Proc Natl Acad Sci U S A. 2006 May 2;103(18):6811-6. Epub 2006 Apr 20.

6.

Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.

Hoogeveen-Westerveld M, Ekong R, Povey S, Mayer K, Lannoy N, Elmslie F, Bebin M, Dies K, Thompson C, Sparagana SP, Davies P, van Eeghen AM, Thiele EA, van den Ouweland A, Halley D, Nellist M.

Hum Mutat. 2013 Jan;34(1):167-75. doi: 10.1002/humu.22202. Epub 2012 Oct 11. Erratum in: Hum Mutat. 2013 Feb;34(2):408-10. van Eeghen, Agnies M [added]; Thiele, Elizabeth A [added].

PMID:
22903760
7.

Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT.

Cancer Res. 2010 Feb 1;70(3):1053-62. doi: 10.1158/0008-5472.CAN-09-3722. Epub 2010 Jan 26.

8.

Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD.

Saito Y, Tanaka Y, Aita Y, Ishii KA, Ikeda T, Isobe K, Kawakami Y, Shimano H, Hara H, Takekoshi K.

Am J Physiol Endocrinol Metab. 2012 Mar 15;302(6):E615-25. doi: 10.1152/ajpendo.00035.2011. Epub 2011 Aug 30.

9.

mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.

Zhang Y, Xu S, Lin J, Yao G, Han Z, Liang B, Zou Z, Chen Z, Song Q, Dai Y, Gao T, Liu A, Bai X.

Breast Cancer Res Treat. 2012 Nov;136(2):379-88. doi: 10.1007/s10549-012-2270-7. Epub 2012 Sep 29.

PMID:
23053656
10.

Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.

Kim SH, Kowalski ML, Carson RP, Bridges LR, Ess KC.

Dis Model Mech. 2013 Jul;6(4):925-33. doi: 10.1242/dmm.011494. Epub 2013 Mar 27.

11.

TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice.

Abs E, Goorden SM, Schreiber J, Overwater IE, Hoogeveen-Westerveld M, Bruinsma CF, Aganović E, Borgesius NZ, Nellist M, Elgersma Y.

Ann Neurol. 2013 Oct;74(4):569-79. doi: 10.1002/ana.23943. Epub 2013 Sep 10.

PMID:
23720219
12.

A systems-level interrogation identifies regulators of Drosophila blood cell number and survival.

Sopko R, Lin YB, Makhijani K, Alexander B, Perrimon N, Brückner K.

PLoS Genet. 2015 Mar 6;11(3):e1005056. doi: 10.1371/journal.pgen.1005056. eCollection 2015 Mar.

13.

Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.

Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F.

Breast Cancer Res. 2011 Jun 21;13(3):R66. doi: 10.1186/bcr2903.

14.

Sunitinib, a small-molecule receptor tyrosine kinase inhibitor, suppresses neointimal hyperplasia in balloon-injured rat carotid artery.

Ishii S, Okamoto Y, Katsumata H, Egawa S, Yamanaka D, Fukushima M, Minami S.

J Cardiovasc Pharmacol Ther. 2013 Jul;18(4):359-66. doi: 10.1177/1074248412472258. Epub 2013 Jan 15.

PMID:
23324994
15.

Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.

Takeuchi A, Eto M, Shiota M, Tatsugami K, Yokomizo A, Kuroiwa K, Itsumi M, Naito S.

Int J Oncol. 2012 May;40(5):1691-6. doi: 10.3892/ijo.2012.1368. Epub 2012 Feb 13.

PMID:
22344606
16.

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248.

Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB.

Mol Cancer Ther. 2006 May;5(5):1280-9.

17.

A role for p38 stress-activated protein kinase in regulation of cell growth via TORC1.

Cully M, Genevet A, Warne P, Treins C, Liu T, Bastien J, Baum B, Tapon N, Leevers SJ, Downward J.

Mol Cell Biol. 2010 Jan;30(2):481-95. doi: 10.1128/MCB.00688-09. Epub 2009 Nov 16.

18.

Systematic combination screening reveals synergism between rapamycin and sunitinib against human lung cancer.

Li X, Tong LJ, Ding J, Meng LH.

Cancer Lett. 2014 Jan 1;342(1):159-66. doi: 10.1016/j.canlet.2013.08.046. Epub 2013 Sep 7.

PMID:
24018642
19.
20.

The TSC1-TSC2 complex consists of multiple TSC1 and TSC2 subunits.

Hoogeveen-Westerveld M, van Unen L, van den Ouweland A, Halley D, Hoogeveen A, Nellist M.

BMC Biochem. 2012 Sep 24;13:18. doi: 10.1186/1471-2091-13-18.

Items per page

Supplemental Content

Write to the Help Desk